



Fig. 1/8




Local progestin administration induces dose-dependent weight in the IUS-carrying right uterine horn (R). The left uterine horn (L) does not carry an IUS and does not show any weight gain.

Fig. 2/8



Local progestin administration induces dose-dependent weight gain in the IUS-carrying right uterine horn (R). The left uterine horn (L) does not carry an IUS and does not show weight gain.

FIG. 3/8




d = day

No decrease in LH levels occurs with compound (A) up to a dosage of 3.5 µg.

No decrease in LH levels occurs with compound (B) up to a dose range of 45 µg.

FIG. 4/8




d = day

No decrease in LH levels occurs with compound (A) up to a dosage of 3.5µg.

No decrease in LH levels occurs with compound (B) up to a dosage of 45µg.


FIG. 5/8



Compound (A) exhibits a distinct increase in gene expression in the dose range from 1 µg/day upwards.

Levonorgestrel exhibits a distinct increase in gene expression in the dose range from 8 µg/day upwards.

FIG. 6/8



Compound (A) exhibits a distinct increase in gene expression in the dose range from 1 µg/day upwards.

Levonorgestrel exhibits a distinct increase in gene expression in the dose range from 8 µg/day upwards.

FIG. 7/8

In-vitro release rates of compound A in 2-hydroxypropyl- β -cyclodextrin




FIG. 8/8

In-vitro release rates of compound A in 2-hydroxypropyl- β -cyclodextrin

